Becton, Dickinson Gets FDA Emergency Use Approval For Covid-19 Test
July 06 2020 - 8:43AM
Dow Jones News
By Micah Maidenberg
Becton, Dickinson & Co. said Monday federal health
regulators have signed off on its rapid test for Covid-19 under a
special program designed to speed approvals of such products.
Becton said the U.S. Food and Drug Administration granted an
emergency use authorization for a point-of-care test for Covid-19
that delivers results in 15 minutes.
The test, Becton said, can be used on its BD Veritor Plus
System, a device that provides test results and is targeted for
healthcare providers, lab workers in physician offices and others
in the health sector.
Other companies with medical device businesses also have
received permission under the FDA's emergency use program for
point-of-care tests designed to detect Covid-19 on their diagnostic
systems, including Abbott Laboratories.
Becton said its BD Veritor system, a bit larger than a mobile
phone, is currently in use in more than 25,000 locations.
The company expects to have capacity in place to produce two
million of the Covid-19 tests per week by the end of September.
The tests will offer "results in real-time at convenient
locations like retail pharmacies, urgent care centers and doctors'
offices," said Dave Hickey, president of Becton's integrated
diagnostic solutions business.
On Sunday, more than 49,000 people in the U.S. contracted the
coronavirus, according to Johns Hopkins University.
Write to Micah Maidenberg at micah.maidenberg@wsj.com
(END) Dow Jones Newswires
July 06, 2020 08:28 ET (12:28 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Becton Dickinson (NYSE:BDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Becton Dickinson (NYSE:BDX)
Historical Stock Chart
From Apr 2023 to Apr 2024
